RxDoctor Payments Data

William Coleman, MD

Addiction Psychiatry · Albany, GANPI 1134157381

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 64 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by Sunovion Pharmaceuticals Inc. at 25.9% of the total. Reporting peaked in 2019 at $327 and has fallen 74.3% since, to $84 in 2025.

$1,072in general payments, 2019–2025

Across 64 payments — averaging $16.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sunovion Pharmaceuticals Inc.$278
  • Indivior Inc.$169
  • AbbVie$102
  • Vanda Pharmaceuticals Inc.$98
  • Johnson & Johnson$75
  • Braeburn Inc.$63
  • plus $286 from 10 others
$1,027in research payments, 2019–2025

Across 2 payments — averaging $513.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$1K

What the payments were for

  • Food & beverage$1,072100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,072 in reported general payments places this provider in the 75th percentile of 22 addiction psychiatry providers in Georgia.

See all addiction psychiatry providers in Georgia

Medicare billing

Part B allowed, 2024
$27,978
Medicare patients
48
Services billed
294

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl40$5,802
Buprenorphine Hcl132$5,154
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine16$1,438
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine47$1,330
Bupropion XlBupropion Hcl24$1,268
Dexmethylphenidate Hcl ErDexmethylphenidate Hcl12$1,197
Alprazolam92$688
Fluoxetine Hcl18$559
Quetiapine Fumarate40$365
Zolpidem Tartrate54$327
Lorazepam46$278
Mirtazapine27$277
Lamotrigine18$231
Risperidone44$209
Clonazepam63$202

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Almatica Pharma LLCSertraline Hcl$50$4719 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 22 addiction psychiatry providers in Georgia.

Other addiction psychiatry in Albany

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →